NTLA vs TRIB
Intellia Therapeutics, Inc. and Trinity Biotech PLC, side by side — 9 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NTLA | TRIB |
|---|---|---|
| Revenue | $67.7M | $61.6M |
| Net income | $-412.7M | $-31.8M |
| Gross margin | 100.0% | 34.8% |
| Net margin | −609.9% | −51.6% |
| Return on equity | −53.5% | — |
| Diluted EPS | −$3.81 | — |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-395.9M | $-4.6M |
| Equity | $671.4M | — |
| Net debt / equity | — | — |
| Current ratio | 5.08× | 1.28× |
| Revenue CAGR 5y | 3.1% | −7.4% |
| Profit CAGR 5y | — | — |
NTLA and TRIB book revenue within 15% of each other, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
9 years side by side
| Fiscal year | NTLA | TRIB |
|---|---|---|
| FY2024 | $57.9M | $61.6M |
| FY2023 | $36.3M | $56.8M |
| FY2022 | $52.1M | $62.5M |
| FY2021 | $33.1M | $81.1M |
| FY2020 | $58.0M | $102.0M |
| FY2019 | $43.1M | $90.4M |
| FY2018 | $30.4M | $97.0M |
| FY2017 | $26.1M | $99.1M |
| FY2016 | $16.5M | $99.6M |
Net income by year
Bottom line
| Fiscal year | NTLA | TRIB |
|---|---|---|
| FY2024 | $-519.0M | $-31.8M |
| FY2023 | $-481.2M | $-24.0M |
| FY2022 | $-474.2M | $-41.0M |
| FY2021 | $-267.9M | $875,000 |
| FY2020 | $-134.2M | $-6.4M |
| FY2019 | $-474.2M | $-28.9M |
| FY2018 | $-85.3M | $-22.1M |
| FY2017 | $-67.5M | $-40.3M |
| FY2016 | $-31.6M | $-100.6M |
Advertisement
AdSense · Rectangle 336×280
More in this industry